Szczepionka przeciwko afrykańskiemu pomorowi świń - gdzie jesteśmy i dokąd zmierzamy
Type
Journal article
Language
Polish
Date issued
2022
Author
Faculty
Wydział Medycyny Weterynaryjnej i Nauk o Zwierzętach
Journal
Życie Weterynaryjne
ISSN
0137-6810
Number
6
Pages from-to
378-384
Abstract (EN)
African swine fever (ASF), is a viral disease of pigs and wild boar that is usually deadly. There are neither vaccines nor cures. African swine fever has got a significant negative impact on the global pig industry. The disease control is based on ensuring biosecurity, early diagnosis and culling pig herds with ASFVinfected animals. However, in view of the ease with which ASFV spreads, its
high resistance to environmental conditions and the many difficulties related to the introduction of effective specific immunoprophylaxis, this process is extremely difficult. Despite incountering problems such as lack of an animal model other than the natural host, lack of an effective continuous cell line for the isolation and propagation of ASFV, a risk of reversion to virulence, or inability to differentiate infected animals from vaccinated ones, scientists do not stop trying to design an effective vaccine. Recent approaches to ASF vaccine construction have focused on the development of modified live vaccines by targeted gene deletion from different isolates or of subunit vaccines. Here, we discuss current scientific advances and technological progress in this issue. The design of a safe and effective vaccine against ASFV seems to be achievable, nevertheless, a commercial vaccine is unlikely to appear within the next few years.
high resistance to environmental conditions and the many difficulties related to the introduction of effective specific immunoprophylaxis, this process is extremely difficult. Despite incountering problems such as lack of an animal model other than the natural host, lack of an effective continuous cell line for the isolation and propagation of ASFV, a risk of reversion to virulence, or inability to differentiate infected animals from vaccinated ones, scientists do not stop trying to design an effective vaccine. Recent approaches to ASF vaccine construction have focused on the development of modified live vaccines by targeted gene deletion from different isolates or of subunit vaccines. Here, we discuss current scientific advances and technological progress in this issue. The design of a safe and effective vaccine against ASFV seems to be achievable, nevertheless, a commercial vaccine is unlikely to appear within the next few years.
Keywords (EN)
License
Other
Open access date
June 2022